Cessatech and Ventis Pharma enter a co-development and commercialization royalty license agreement for CT001 sharing net profits- CT001 will be part of US Ventis Pharma's distribution of innovative pain management therapies under an early access program in the US
- A large US market of more than 15 million pediatric injuries or procedural pain incidents, categorized as moderate to severe, giving the partnership a large market opportunity, with potential for revenues in 2024
On 27 June -
The deal leverages Ventis Pharma's experience in the US regulatory and commercial landscape for pain management and CT001 will join other therapies in the company's portfolio being used by selected US hospitals under an early access program governed by the FDA. In parallel to offering CT001 under an early access program, Ventis will build on the late-stage development work already carried out by
Jes Trygved, CEO
"The US is the largest market and we believe the partnership with Ventis represents the best opportunity to get CT001 to a much-needed pain management of children. With this partnership CT001 can potentially be available to patients in the US already by the next year - which is 3-4 years earlier than originally anticipated - as we leverage the skills and operations of our partner. This collaboration is a good illustration of our strategy to build our business by working with partners who can help us successfully navigate the regulatory and commercial landscape in different territories. Ventis will potentially also be involved in the further development of our pipeline within pain management. We are truly excited about this partnership"
"The partnership between
About the US market
There are more than 15 million pediatric injuries or procedural pain incidents (categorized as moderate to severe) requiring medical treatment annually in the US. The majority of these incidents are in a hospital setting (emergency rooms and pediatric hospital units) but also occur in pre-hospital settings such as ambulances. Current pain management regimes for children typically involve the injection of pain relief treatments. CT001 provides a unique needle free solution to manage pediatric pain incidents.
For more information about
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com
For more information about Ventis Pharma, please contract:
Phone: +1 800-441-5841
Email: tpatrick@ventispharma.com
www.ventispharma.com
About
About Ventis Pharma
https://news.cision.com/cessatech/r/cessatech-and-ventis-pharma-announce-us-partnership-for-ct001,c3794677
https://mb.cision.com/Main/19921/3794677/2153940.pdf
(c) 2023 Cision. All rights reserved., source